Skip to main content

Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences

Written by Customer Service on . Posted in Public Companies.

BRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences:

Event: Dawson James Securities 7th Annual Small Cap Growth Conference
Date: Wednesday, October 12, 2022
Webcast: Conference Registration Link
Archived Recording: ir.hillstreambio.com
Time: Please check with the conference coordinator as presentation times are subject to change.
Location: Wyndham Grand Hotel in Jupiter, Florida

Event: ThinkEquity Conference
Date: Wednesday, October 26, 2022
Webcast: Conference Registration Link
Archived Recording: ir.hillstreambio.com
Time: Please check with the conference coordinator as presentation times are subject to change.
Location: The Mandarin Oriental Hotel in New York

About Hillstream BioPharma Inc.
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers. Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer and epithelial carcinomas. Hillstream intends to initiate IND discussions with the FDA in first half of 2023. Hillstream uses Quatramer™, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity. For more information, please visit www.hillstreambio.com.

Investor Contact:
investorrelations@hillstreambio.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.